Aortic Stenosis (AS) is a common condition with an estimated pooled prevalence of all AS in the elderly population at around 12.4%, with that of severe AS estimated to be around 3.4%. In the past, surgical aortic valve replacement was the primary treatment option for severe AS for decades. However, with the compelling evidence on the safety and efficacy of transcatheter aortic valve replacement (TAVR), it has become the gold standard treatment option for many patients with symptomatic severe AS. Transfemoral access has been the preferred method for transcatheter heart valve delivery. However, the prevalent use of TAVR on a diverse patient profile with different risk factors, such as peripheral artery disease, precluded the possibility of a transfemoral approach despite the improvement of valves and delivery systems technology. Therefore, alternative TAVR approaches have gained increasing utility in cases where transfemoral access is unfavorable. We review the journey, evolution, and techniques for different approaches of percutaneous TAVR, including transfemoral, transcarotid, transsubclavian/transaxillary, and transcaval approaches, in addition to the traditional “surgical” transaortic and transapical accesses. Consolidating these data highlights each approach's practicality and limitations, providing additional grounding for case-by-case utilization and future clinical research.
11 December 2023 in Interventional Cardiology: Reviews, Research, Resources
Percutaneous coronary intervention with stent implantation is an integral aspect of minimally interventional cardiac procedures. The technology and techniques behind stent design and implantation have evolved rapidly over several decades. However, continued discourse remains around optimal peri- and post-interventional management with dual antiplatelet therapy to minimise both major cardiovascular or cerebrovascular events and iatrogenic bleeding risk. Standard guidelines around dual antiplatelet therapy historically recommended long-term dual antiplatelet therapy for 12 months (with consideration for >12 months in certain patients); however, emerging data and generational improvements in the safety of drug-eluting stents have ushered in a new era of short-term therapy to reduce the incidence of major bleeding events. This case review will provide an overview of the current state of guidelines around duration of dual antiplatelet therapy and examine recent updates and continued gaps in existing research.
12 August 2025 in Methodist DeBakey Cardiovascular Journal
The development of catheter-based interventions has revolutionized the treatment of coronary artery disease (CAD), from the first heart catheterization in 1929 to the emergence of drug-coated balloons (DCBs) as a treatment for in-stent restenosis (ISR). This review explores the evolution and clinical application of DCBs in CAD, with a particular focus on their role in managing ISR, de novo coronary disease, and complex lesions. DCBs deliver antiproliferative drugs such as paclitaxel or sirolimus to the vessel wall and have emerged as a promising alternative to traditional stent-based therapies, reducing the need for permanent metallic implants and associated thrombotic risks. Early research demonstrated the effectiveness of DCBs in ISR, and recent studies have expanded their application to small vessel disease, bifurcation lesions, and long diffuse lesions. Notably, DCBs have shown non-inferiority to drug-eluting stents in certain cases, including high-risk patients and those with complex coronary anatomy. Despite some challenges, such as the potential for coronary dissection and the need for optimal lesion preparation, DCBs have demonstrated strong potential in reducing restenosis and improving long-term outcomes in a variety of patient populations. While further studies are required to refine their use in off-label indications, DCBs may represent a versatile, effective, and safer approach in the management of CAD.
As transcatheter tricuspid valve replacement with the EVOQUE system gains wider clinical adoption, growing experience has highlighted key anatomical considerations that influence procedural success. While right transfemoral (TF) access is the standard approach, it can be technically challenging in patients with complex right heart anatomy, such as low right atrium (RA) height or a large inferior vena cava–tricuspid valve annulus (IVC-TVA) offset. These factors may lead to suboptimal trajectory, impaired coaxiality, and difficult valve deployment. Left TF access offers a potential alternative by providing additional RA height and a more favorable lateral trajectory, allowing improved alignment with the tricuspid valve annulus (TVA). This approach is particularly useful in patients with large short-axis (SAX) offsets (>20 mm) or steep long-axis angles where right TF access may not achieve perpendicular orientation despite secondary catheter flexion. Using a preprocedural cardiac computed tomography angiography (CCTA) scan, anatomical factors such as RAH, leaflet tethering height, RV depth, and papillary muscle location can be evaluated to guide access planning. While left TF access introduces its own technical considerations, including venous tortuosity, excessive unwanted RA height, and increased need for primary flex, it may expand procedural feasibility in anatomically challenging cases. This review outlines real-world scenarios where left-sided access was favored, supporting its use as a safe and effective strategy in selected patients. Further studies are warranted to assess long-term outcomes and to inform the design of next-generation delivery systems capable of accommodating broader anatomical variation.
8 June 2025 in Catheterization and Cardiovascular Interventions